Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2423786rdf:typepubmed:Citationlld:pubmed
pubmed-article:2423786lifeskim:mentionsumls-concept:C0003195lld:lifeskim
pubmed-article:2423786lifeskim:mentionsumls-concept:C0021252lld:lifeskim
pubmed-article:2423786lifeskim:mentionsumls-concept:C0441472lld:lifeskim
pubmed-article:2423786lifeskim:mentionsumls-concept:C1517004lld:lifeskim
pubmed-article:2423786lifeskim:mentionsumls-concept:C0332120lld:lifeskim
pubmed-article:2423786pubmed:dateCreated1986-7-15lld:pubmed
pubmed-article:2423786pubmed:abstractTextThe effects of indoramin on cardiac conduction and its antifibrillatory action were investigated and compared with those of mexiletine (class I antiarrhythmic agent), sotalol, and prazosin. In isolated guinea pig atria, indoramin 1 microgram/ml reduced spontaneous rate by 31 +/- 1.0% (mean +/- SE, n = 6) and maximal driving frequency by 25 +/- 1.2% (n = 4). Mexiletine 3 micrograms/ml reduced maximal driving frequency by 35 +/- 1.4% (n = 4) but reduced spontaneous rate by only 13 +/- 2.0% (n = 4). In isolated, perfused, electrically driven (2.5 Hz) guinea pig hearts, indoramin 1 microgram/ml increased the ST interval by 22 +/- 1.9% (n = 6) with no effect on the QRS interval. Higher concentrations (3 micrograms/ml) also increased the QRS interval by 21 +/- 4.0%. In anaesthetized cats, indoramin 6 mg/kg i.v. (infused over 30 min) reduced systolic blood pressure by 36 +/- 3.6% (n = 6) and heart rate by 35 +/- 2.2%, and increased the ST interval by 31 +/- 5.3% and the effective refractory period by 45 +/- 3.2% but had little or no effect on the QRS interval (12 +/- 2.9%) and diastolic electrical stimulation threshold (7 +/- 6.8%). Indoramin 10 mg/kg increased the QRS interval and diastolic electrical stimulation threshold by 20 +/- 2.8 and 23 +/- 2.5%, respectively. Analogous experiments with mexiletine 15 mg/kg showed little changes in cycle length (7 +/- 1.3%), effective refractory period (21 +/- 2.8%), and the ST interval (6 +/- 2.5%); however, there was a marked increase in diastolic threshold (91 +/- 8.9%). Sotalol 15 mg/kg had a cardiac profile similar to that of indoramin.(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:2423786pubmed:languageenglld:pubmed
pubmed-article:2423786pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2423786pubmed:citationSubsetIMlld:pubmed
pubmed-article:2423786pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2423786pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2423786pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2423786pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2423786pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2423786pubmed:statusMEDLINElld:pubmed
pubmed-article:2423786pubmed:issn0160-2446lld:pubmed
pubmed-article:2423786pubmed:authorpubmed-author:HarperS TSTlld:pubmed
pubmed-article:2423786pubmed:issnTypePrintlld:pubmed
pubmed-article:2423786pubmed:volume8 Suppl 2lld:pubmed
pubmed-article:2423786pubmed:ownerNLMlld:pubmed
pubmed-article:2423786pubmed:authorsCompleteYlld:pubmed
pubmed-article:2423786pubmed:paginationS131-6lld:pubmed
pubmed-article:2423786pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:2423786pubmed:meshHeadingpubmed-meshheading:2423786-...lld:pubmed
pubmed-article:2423786pubmed:meshHeadingpubmed-meshheading:2423786-...lld:pubmed
pubmed-article:2423786pubmed:meshHeadingpubmed-meshheading:2423786-...lld:pubmed
pubmed-article:2423786pubmed:meshHeadingpubmed-meshheading:2423786-...lld:pubmed
pubmed-article:2423786pubmed:meshHeadingpubmed-meshheading:2423786-...lld:pubmed
pubmed-article:2423786pubmed:meshHeadingpubmed-meshheading:2423786-...lld:pubmed
pubmed-article:2423786pubmed:meshHeadingpubmed-meshheading:2423786-...lld:pubmed
pubmed-article:2423786pubmed:meshHeadingpubmed-meshheading:2423786-...lld:pubmed
pubmed-article:2423786pubmed:meshHeadingpubmed-meshheading:2423786-...lld:pubmed
pubmed-article:2423786pubmed:meshHeadingpubmed-meshheading:2423786-...lld:pubmed
pubmed-article:2423786pubmed:meshHeadingpubmed-meshheading:2423786-...lld:pubmed
pubmed-article:2423786pubmed:meshHeadingpubmed-meshheading:2423786-...lld:pubmed
pubmed-article:2423786pubmed:meshHeadingpubmed-meshheading:2423786-...lld:pubmed
pubmed-article:2423786pubmed:meshHeadingpubmed-meshheading:2423786-...lld:pubmed
pubmed-article:2423786pubmed:meshHeadingpubmed-meshheading:2423786-...lld:pubmed
pubmed-article:2423786pubmed:meshHeadingpubmed-meshheading:2423786-...lld:pubmed
pubmed-article:2423786pubmed:year1986lld:pubmed
pubmed-article:2423786pubmed:articleTitleExperimental evidence for the antiarrhythmic action of indoramin.lld:pubmed
pubmed-article:2423786pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2423786lld:pubmed